-([F]Fluoroethyl)-l-tyrosine ([F]FET) is actively transported into the brain and cancer cells by LAT1 and possibly other amino acid transporters, which enables brain tumor imaging by positron emission tomography (PET). However, tumor delivery of this probe in the presence of competing amino acids may be limited by a relatively low affinity for LAT1. The aim of the present work was to evaluate the -substituted [F]FET analog -[F]FET and the methyl ester [F]FET-OMe, which were designed to improve tumor delivery by altering the physicochemical, pharmacokinetic, and/or transport properties. Both tracers could be prepared with good radiochemical yields of 41-56% within 66-90 min. Preclinical evaluation with [F]FET as a reference tracer demonstrated reduced uptake of [F]FET-OMe by U87 glioblastoma cells and no advantage for tumor imaging. In contrast, -[F]FET showed significantly improved uptake and accelerated tumor accumulation in an orthotopic glioblastoma model. As such, our work identifies -[F]FET as a promising alternative to [F]FET for brain tumor imaging that deserves further evaluation with regard to its transport properties and biodistribution.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11151201 | PMC |
http://dx.doi.org/10.1021/acs.molpharmaceut.3c01215 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!